The FDA’s Allergenic Products Advisory Committee will issue a recommendation on Stallergenes SA’s Oralair grass allergy tablet, a therapy that’s well established in Europe, for first-time approval in the U.S. market. Until now, the FDA has only approved subcutaneous therapies involving allergen extracts. Stallergenes is seeking approval for Oralair to treat allergic rhinitis or conjunctivitis in patients 5 years of age and older.